Skip to Main content Skip to Navigation
Journal articles

Vaccin grippal quadrivalent : quels changements pour quels bénéfices ?

Abstract : Currently, circulating viruses responsible for annual seasonal influenza epidemics belong to two influenza A subtypes, A(H1N1) and A(H3N2), and to two antigenically distinct type B lineages, B/Yamagata and B/Victoria lineages. Like diseases due to influenza A virus, influenza B virus diseases may have severe consequences and should be prevented. Until now, in France, the vaccines used to prevent seasonal influenza were trivalent, systematically targeting viruses belonging to both A subtypes and to one or other of the B lineages. The protective efficacy of trivalent vaccines is diminished during the seasons when viruses belonging to both B lineages cocirculated or when the circulating dominant type B virus belonged to a lineage different from that targeted by the vaccine strain. By targeting viruses belonging to both B lineages, quadrivalent vaccines improve the antigenic concordance between circulating and vaccine type B strains. Three inactivated quadrivalent vaccines are authorized for marketing in France and should be available for the 2018-2019 season. It is expected that, by providing enlarged protection, these quadrivalent influenza vaccines will improve vaccine efficacy, the confidence in immunization of the public, the satisfaction of health professionals, and ultimately will help to complete immunization coverage.
Document type :
Journal articles
Complete list of metadata
Contributor : SCD EHESP Connect in order to contact the contributor
Submitted on : Thursday, January 30, 2020 - 6:23:04 PM
Last modification on : Tuesday, January 25, 2022 - 6:56:09 PM

Links full text



Anne Mosnier, Odile Launay, Luc Martinez, Gaetan Gavazzi, Laurence Josset, et al.. Vaccin grippal quadrivalent : quels changements pour quels bénéfices ?. La Presse Médicale, Elsevier Masson, 2018, 47 (10), pp.842-853. ⟨10.1016/j.lpm.2018.06.013⟩. ⟨hal-02461688⟩



Record views